Autoimmune

Autoimmune-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Genetic polymorphisms associated with rheumatoid arthritis, metods of detection and uses thereof
May 25, 2017 - N°20170145503

The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules ...
NEW Use of mcoln-1 modulators to regulate cell migration
May 25, 2017 - N°20170145423

The present invention relates to the use of modulators of mcoln-1 for modulating the cells migration, in particular the migration of dendritic cells and tumor cells, especially for antitumoral vaccination, autoimmune diseases treatment, and metastasis prevention.
NEW Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
May 25, 2017 - N°20170145417

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, ...
NEW Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Inhibitor of bruton's tyrosine kinase
May 25, 2017 - N°20170144986

Provided are a compound represented by formula (iii) or pharmaceutically acceptable salts, solvates, active metabolites, polymorphs, esters, tautomers or prodrugs thereof, pharmaceutical compositions containing the compound represented by formula (iii), and the application of the pharmaceutical compositions as selective inreversible inhibitor of bruton's tyrosine kinase for the prevention and treatment of inflammation, autoimmune diseases (such as rheumatoid arthritis) associated with ...
NEW Implantable neurostimulator with integral hermetic electronic enclosure, circuit substrate, monolythic feed-through, lead assembly and anchoring ...
May 25, 2017 - N°20170143959

An implantable medical device is provided for the suppression or prevention of pain, movement disorders, epilepsy, cerebrovascular diseases, autoimmune diseases, sleep disorders, autonomic disorders, abnormal metabolic states, disorders of the muscular system, and neuropsychiatric disorders in a patient. The implantable medical device can be a neurostimulator configured to be implanted on or near a cranial nerve to treat headache or ...
NEW Rituximab induction therapy followed by glatiramer acetate therapy
May 25, 2017 - N°20170143824

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The ...
NEW Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Compositions comprising bacterial strains
May 25, 2017 - N°20170143774

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
NEW Compositions comprising bacterial strains
May 25, 2017 - N°20170143773

The invention provides compositions comprising bacterial strains for treating and preventing inflammatory and autoimmune diseases.
NEW Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders
May 25, 2017 - N°20170143727

The present invention provides compounds and methods for preventing and treating an immune disorder in a subject.
NEW Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy ...
May 25, 2017 - N°20170143712

In an embodiment, therapeutic methods and uses of bruton's tyrosine kinase (btk) inhibitors for treatment of cancer, inflammation, immune disorders, and autoimmune disorders, including dermatoses, and for transplantation prophylaxis, based on btk occupancies and/or btk resynthesis rates for b cells in various diseases, tissue compartments, including bone marrow and lymph nodes, are described. In an embodiment, dosing regimens for ...
NEW Selective kinase inhibitors
May 25, 2017 - N°20170143706

The present disclosure relates to methods of modulating (for example, inhibiting) activity of jak3, comprising contacting the jak3 with a compound of formula i or pharmaceutically acceptable salt thereof, wherein constituent members are provided hereinwith. The present disclosure further provides novel compounds and compositions as well as their methods of preparation and use. The disclosed jak3 inhibitors may be used ...
Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin ...
St. Jude Children's Research Hospital
May 18, 2017 - N°20170137524

The invention is directed to treatment of cancer, infections and various inflammatory and autoimmune conditions by affecting regulatory t cell stability and function via a neuropilin-1:semaphorin axis.
Cd3-binding molecules capable of binding to human and non-human cd3
Macrogenics, Inc.
May 18, 2017 - N°20170137519

The present invention relates to cd3-binding molecules capable of binding to human and non-human cd3, and in particular to such molecules that are cross-reactive with cd3 of a non-human mammal (e. G., a cynomolgus monkey). The invention also pertains to uses of such antibodies and antigen-binding fragments in the treatment of cancer, autoimmune and/or inflammatory diseases and other ...
Autoimmune Patent Pack
Download 462+ patent application PDFs
Autoimmune Patent Applications
Download 462+ Autoimmune-related PDFs
For professional research & prior art discovery
inventor
  • 462+ full patent PDF documents of Autoimmune-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Kv1.3 potassium channel antagonists
Conogenetix Biosciences Gmbh
May 18, 2017 - N°20170137470

The present invention relates to compounds which are capable of selectively binding to and inhibiting the activity of the potassium channel kv1. 3. The invention also relates to pharmaceutical compositions comprising such compounds and to the use of said compounds and said pharmaceutical compositions for the treatment or prevention of autoimmune diseases, obesity, parodontitis and/or tissue transplant rejection.
Treatment of autoimmune diseases with deep brain stimulation
Aleva Neurotherapeutics
May 18, 2017 - N°20170136238

Techniques using electrical stimulation for treating an autoimmune disease by means of an implantable pulse generator and at least one electrode. An electrode lead is surgically implanted in a region of the insular cortex to deliver electrical stimulation. The at least one electrode lead and implantable pulse generator contain features that allow the electrical stimulation to be directed to specific ...
Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or ...
Prothena Biosciences Limited
May 11, 2017 - N°20170129954

The invention provides anti-mcam antibodies that inhibit the ability of human mcam to bind a laminin alpha-4 chain and pharmaceutical compositions and pharmaceutical formulations incorporating the same for use in treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica (pmr) or takayasu's arteritis, methods of generating such antibodies, and their use in the manufacture of medicaments for treatment of neuroinflammatory ...
Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine
Kolltan Pharmaceuticals, Inc.
May 11, 2017 - N°20170129947

The present disclosure provides methods for modulating the interaction between a tam ligand and a lipid membrane containing phosphatidyl serine (ptdser). In one example, such methods use a tam receptor agonist having a ptdser-containing lipid bilayer membrane with gas6 and/or protein s bound to the membrane to activate signaling from one or more tam receptors and treat an autoimmune ...
Fused bicyclic heteroaromatic derivatives as kinase inhibitors
Katholieke Universiteit Leuven, K.u.leuven R&d
May 11, 2017 - N°20170129905

A series of fused bicyclic heteroaromatic derivatives of formula (ia) or (ib), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase iiiβ (pi4kiiiβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
Heterocyclic compounds as pi3k-y inhibitors
Katholieke Universiteit Leuven, K.u.leuven R&d
May 11, 2017 - N°20170129899

Or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of pi3k-γ which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Triazolopyridazine derivatives as modulators of tnf activity
Ucb Biopharma Sprl
May 11, 2017 - N°20170129894

A series of substituted [1,2,4]triazolo[4,3-b]pyridazine derivatives of formula (i), being potent modulators of human tnfa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Tyrosine kinase inhibitors
Principia Biopharma Inc.
May 11, 2017 - N°20170129890

The present disclosure provides compounds that are tyrosine kinase inhibitors, in particular bruton tyrosine kinase (“btk”) inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of btk such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.